Preparation and In Vitro Release Property of PLA Microspheres Enclosing Antitumor Agent

Recently, many antitumor agents developed. Irinotecan hycrochloride (CPT) has a great side effect even though it is well effective against the cancer. Drug delivery system (DDS) medicine indicates that the release rate of medicine is constant for a long time. Therefore, in order to materialize the general idea of DDS, we applied microencapsulation technique to prepare biodegradable polymer microspheres (MS) enclosing antitumor drug having no side effect. Polylactide microparticles enclosing antitumor agent were prepared by solvent evaporation method under various operation conditions. The effects of operation parameter on release rate of drug and morphology of microparticles were studied

Novel 1,8-Naphthalimide derivative with an open space for an anion: Unique fluorescence behaviour depending on the binding anion’s electrophilic property

We have designed a novel 1,8-naphthalimide derivative with an open space for an anion. Computational calculation has predicted that the space could trap various anion species and photo-induced charge transfer depending on the anion's electrophilic properties. Indeed, the fluorescence behaviour of the 1,8-naphthalimide derivative complexes with each anion is consistent with the computational prediction

Thermodynamics of the (1,1/2) Ferrimagnet in Finite Magnetic Fields

We investigate the specific heat and magnetisation of a ferrimagnet with gS=1 and S=1/2 spins in a finite magnetic field using the transfer matrix DMRG down to T=0.025J. Ferromagnetic gapless and antiferromagnetic gapped excitations for H=0 lead to rich thermodynamics for H > 0. While the specific heat is characterized by a generic double peak structure, magnetisation reveals two critical fields, Hc1=1.76(1) and Hc2=3.00(1) with square-root behaviour in the T=0 magnetisation. Simple analytical arguments allow to understand these experimentally accessible findings.Comment: 5 pages, 7 eps figures, uses RevTeX, submitted to PR

大腸癌肺転移切除例の検討

The objective of this study was to evaluate prognostic factors after pulmonary resection for metastasis of colorectal cancer. We retrospectively analyzed the clinicopathological factors and the prognosis of 36patients who received pulmonary resection for metastasis of colorectal cancer. The 5-year overall survival after pulmonary resection was 75.4％, and the 3-year disease free survival after pulmonary resection was 53.5％. There was no significant prognostic factor regarding overall survival after pulmonary resection by multivariate analysis. However, regarding disease-free survival after pulmonary resection, T4 stage colorectal cancer showed significant poorer prognosis by multivariate analysis（p＝0.014）. Patients who received reoperation for pulmonary recurrence showed better prognosis than patients who did not receive reoperation (p＝ 0.04). Prognosis after pulmonary resection for metastasis of colorectal cancer is favorable owing to progresses of chemotherapies. Metastasectomy may not be the primary therapy for patients with pulmonary metastasis from T4 stage colorectal cancer because of their short disease-free survival after metastasectomy. Reoperation for resectable recurrence of pulmonary metastasis may improve overall survival

ハイガン ロボット シュジュツ ノ シヒ リョウキン セッテイ

In Japan, the only robot surgery covered by health insurance is prostatectomy. Robot surgery for pulmonary cancer has not been approved as advanced health care, and hospitals are required to set out-of-pocket fees for surgery on their own. We calculated the fee not covered by insurance to be 1.28million yen, taking into account expenses for : （1） the use of medical equipment, （2） maintenance, （3） labor costs, and （4） medical materials and drugs. Since the fees for surgery plus hospitalization are actually incurred by patients, whether or not the hospitalization fee should be included in out-of-pocket medical fees is decided by each health care institution. In any case, it is necessary to provide patients with a summary of medical fees prior to surgery. Hospitals are required to collect data on pulmonary robot surgical cases while operating the system with medical fees incurred by individual patients